Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies
November 28, 2022 08:00 ET
|
Enlivex Therapeutics Ltd
IND filing followed encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival benefit when Allocetra™ was...
GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
November 10, 2022 15:15 ET
|
GT Biopharma, Inc.
Poster #1: Tri-specific killer engagers target natural killer cells towards mesotheliomaPoster #2: Enhancing NK cell function in the 'cold' tumor microenvironment of prostate cancer with a novel...
Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022
September 12, 2022 08:00 ET
|
Enlivex Therapeutics Ltd
Currently used cisplatin-based combination treatments have limited efficacy against mesothelioma, which is one of the deadliest solid cancers Combining cisplatin with Allocetra™ led to a...
Constellation Pharmaceuticals Presents Phase 1 Data for CPI-0209 at ASCO Annual Meeting
June 04, 2021 09:00 ET
|
Constellation Pharmaceuticals , Inc.
Pharmacodynamic data show comprehensive target engagement after treatment with CPI-0209 monotherapyOral, once-daily 350mg dose selected for Phase 2Enrollment of tumor-specific expansion cohorts is...
Momotaro-Gene Announces First Patient Dosed in Phase 2 Clinical Trial of MTG201 in Combination with Nivolumab in Patients with Relapsed Malignant Pleural Mesothelioma
September 11, 2019 07:30 ET
|
Momotaro-Gene
OKAYAMA, Japan, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Momotaro-Gene, a clinical-stage biotherapeutics company developing novel gene therapies for the treatment of cancer, today announced the dosing of...
Harpoon Therapeutics Doses First Patient with a Mesothelin-Targeting T cell Engager (HPN536) in Phase 1/2a Clinical Trial for Ovarian and Other Solid Tumor Cancers
April 18, 2019 07:30 ET
|
Harpoon Therapeutics
HPN536 is the second TriTAC T cell engager to enter clinical development from the Harpoon pipeline Trial initiated at Sarah Cannon Research Institute in Nashville, Tenn. - a leading drug development...
Attorney Michael Shepard named a 2018 Lawyer of the Year by Massachusetts Lawyers Weekly After Landmark Industry Verdict
January 29, 2019 10:52 ET
|
Shepard Law, P.C.
BOSTON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Michael Shepard, founder of Shepard Law, one of the top asbestos personal injury law firms in Massachusetts, was selected by Massachusetts Lawyers Weekly as...
Jury Awards $6.8 Million Verdict to Mesothelioma Victim’s Widow
October 02, 2017 09:50 ET
|
Thornton Law Firm
Boston, Massachusetts, Oct. 02, 2017 (GLOBE NEWSWIRE) -- A Superior Court jury in Boston returned a verdict of $6.8 million dollars against New England Insulation, a Canton company that distributed...
Mesothelioma Victim Receives Record Asbestos Verdict in New England
September 21, 2017 11:56 ET
|
Thornton Law Firm
BOSTON, Mass., Sept. 21, 2017 (GLOBE NEWSWIRE) -- A Superior Court jury in Boston returned a verdict of $7.55 million dollars against New England Insulation, a Canton company that distributed and...
Selecta Biosciences Obtains License for Recombinant Immunotoxin LMB-100 from National Cancer Institute (NCI) for Pancreatic Cancer, Mesothelioma and Other Cancers
May 02, 2017 08:00 ET
|
Selecta Biosciences
NCI Currently Conducting Clinical Trials with LMB-100LMB-100 and SVP-Rapamycin Combination Treatment Enhances Anti-Tumor Activity in Preclinical Models Selecta and NCI in Discussions Regarding Phase...